跳至主要内容
临床试验/CTRI/2024/08/072000
CTRI/2024/08/072000尚未招募不适用

A single blind observational study to evaluate the safety and efficacy of polyherbal formulation in the management of Niqris (Gout).

Islamic University of Science and Technology1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年8月15日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
1. Serum uric acid level.

研究概览

简要总结

Niqris (Gout) is one of the most common types of inflammatory jointdiseases creating difficulty and problems in day to day life. Itis characterized by recurrent attacks of acute pain and swelling primarily affecting one joint usually the metatarso-phalangeal joint of big toe and small joints of feet and hands, commonly affects both feet.The prevalence of Gout varies between population but is approximately 1-2% and out of the affected population males are more common while females of the postmenopausal group are at high risk. According to Hippocrates, it occurs rarely in children and premenopausal women and does not occur in transgenders.Six centuries later to Buqrat,  Jalinoos was the first to describe tophi. An excessive intake of food containing high purine contents (Baadi Ghiza) is the primary or essential cause of Gouty Arthritis (Niqris), which results in deposition of Maddah-e-Niqris (urates or tophi), in the articular and periarticular tissues.In modern medicine NSAID’s, Uricosuric drugs, colchicine, glucocorticoids etc. are used for subsiding acute attacks or lowering serum uric acid which is associated with potent adverse effects like vomiting, GI bleeding, hepato-renal toxicity, hypersensitivity etc. The side effects of all above-mentioned drugs call for the development of novel drugs or methods of treatment used with similar and better efficacy and lesser toxicity than presently available drugs.Now a days Unani system of Medicine is getting authentication for the treatment of such type of disease by its unique concept which is equilibrium of humors, for this purpose different methods of treatment are applied like Ilaj bil Giza (Dietotherapy), Ilaj bil Dawa (Pharmacotherapy) , Ilaj bil Tadbeer (Rehimenal Therapy), and Ilaj bil Yad (Surgery). The Unani medicines being having less side effects are more beneficial, thus the present study has been designed to study the efficacy and safety of the poly herbal formulation, constituting the drugs namely Suranjan (ColchicumLuteum), Khulanjan (Alpinia Galanga) and Bozidan (Pyrethrum Indicum)

Diagnostic Criteria: Patients with classical sign and symptom of Niqris (Gout) with uric acid level more than 7mg/dl.

Study design: Single blind, observational study.Sample size: 30 patients

Intervention.

Test group: Powder of Suranjan, Khulanjan and Bozidan.

Method of Prepration: The drugs will be grinded into fine powder and all will be mixed properly.

Dosage: 5 gm of each drug ie a total of 15grams of drug will be given in three divided doses every day.

**Route of Administration:**Oral

Duration   of Protocol: 60 days with follow up as ( 15th, 30th,45th,60th)

Duration of Study: 2 years

Procedure of study:

Enrolled cases of Gout will be recruited after obtaining a written informed consent.

The pre and post treatment subjective and objective findings (effects) will be compared and its significance will be evaluated through a suitable statistical test.

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • •1.Patients of either sex will be selected for the study.
  • •2.Between 18 to 60 years of age.
  • •3.Fulfilling the criteria of American College of Rheumatology for diagnosing Gouty Arthritis including clinical features, laboratory, and radiological finding will be included in the study, who had serum Uric Acid level more than 7mg/dl.

排除标准

  • •1.Patients below 18 and above 60 years of age.
  • •2.Pregnant and Lactating mothers.
  • •3.Patients who fail to give consent.
  • •4.Patients of Gout associated with any systemic disorder which interfere with patient study will be excluded.
  • •5.Patients of Gout associated with any severe Arthritis condition.
  • •Such as Rheumatoid arthritis, Septic arthritis will be excluded from the study 6.Patients suffering from Anemia and other blood dyscrasias like leukemia, hemophilia etc 7.Patients with history of suffering with congenital Gout.

结局指标

主要结局

1. Serum uric acid level.

时间窗: 2 years

2. CRP

时间窗: 2 years

3. ESR

时间窗: 2 years

次要结局

  • 1 Pain Tenderness and Swelling in the affected joints(2 Difficulty in movement.)

研究者

发起方
Islamic University of Science and Technology
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Tabasum Fatima

Islamic University of Science and Technology

研究点 (1)

Loading locations...

相似试验